Heme Catabolic Pathway in Inflammation and Immune Disorders

In recent years, the heme catabolic pathway is considered to play an important regulatory role in cell protection, apoptosis, inflammation, and other physiological and pathological processes. An appropriate amount of heme forms the basic elements of various life activities, while when released in la...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 10; p. 825
Main Authors Wu, Bing, Wu, Yanwei, Tang, Wei
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.07.2019
Subjects
biliverdin
carbon monoxide
heme
heme oxygenase
immune disorders
inflammation
Pharmacology
heme oxygenase
carbon monoxide
heme
inflammation
biliverdin
immune disorders
Online AccessGet full text

Cover

More Information
Summary:In recent years, the heme catabolic pathway is considered to play an important regulatory role in cell protection, apoptosis, inflammation, and other physiological and pathological processes. An appropriate amount of heme forms the basic elements of various life activities, while when released in large quantities, it can induce toxicity by mediating oxidative stress and inflammation. Heme oxygenase (HO) -1 can catabolize free heme into carbon monoxide (CO), ferrous iron, and biliverdin (BV)/bilirubin (BR). The diverse functions of these metabolites in immune systems are fascinating. Decades work shows that administration of degradation products of heme such as CO and BV/BR exerts protective activities in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS) and other immune disorders. This review elaborates the molecular and biochemical characterization of heme catabolic pathway, discusses the signal transduction and immunomodulatory mechanism in inflammation and summarizes the promising therapeutic strategies based on this pathway in inflammatory and immune disorders.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Paola Patrignani, Università degli Studi G. d’Annunzio Chieti e Pescara, Italy
This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology
Reviewed by: Frank Wagener, Radboud Institute for Molecular Life Sciences, Netherlands; Melania Dovizio, Università degli Studi G. d’Annunzio Chieti e Pescara, Italy
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2019.00825